GLP-1 Drugs Like Ozempic Linked to 30% Lower Breast Cancer Risk in Major Study
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
20 articles
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
New study shows PCSK9 inhibitor prevents cardiovascular events in high-risk diabetes patients without existing heart disease.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
Experimental PCAI compounds blocked over 90% of pancreatic cancer cell migration and triggered self-destruction by hyperactivating tumor growth pathways.
Researchers discovered why fibrolamellar carcinoma resists immunotherapy and found an existing drug can free trapped T cells to fight it.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
New research reveals why BET inhibitor cancer drugs work in labs but fail in patients, pointing to better treatment strategies.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
Breakthrough non-invasive device offers new hope for pancreatic cancer patients with at-home treatment option.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
Glycidol, a toxic compound formed during oil refining, damages DNA and may explain higher cancer rates in fried food consumers.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.